ULTRASOUND AND MALIGNANT TRANSFORMATION IN VITRO

超声与体外恶性转化

• 批准号: 3179891
• 负责人: GEORGE H HARRISON
• 金额: $ 6.91万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 1985
• 资助国家: 美国
• 起止时间: 1985-07-01 至 1987-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3179891
• 关键词: X ray; cancer risk; chromosome disorders; neoplastic transformation; phorbols; radiation carcinogenesis; tissue /cell culture; tumor promoters; ultrasound biological effect

We propose to assess the oncogenic risk of ultrasound, using the C3H/10T1/2 in vitro assay for malignant transformation. This assay is a more direct and quantitative measure of oncogenic risk than are assays of mutation or chromosomal alterations. Ultrasonic beams configured to simulate diagnostic and therapeutic conditions will be used to irradiate cells alone, in combination with carcinogenic treatment (2 Gy of 100-kVp X rays), or followed by post-treatment culturing in 0.1 Mug/ml of 12-0-tetradecanoyl-phorbol-13-acetate (TPA) in order to investigate the possible oncogenic interaction of co-stressors and tumor promotors with ultrasound. Experiments will be designed to detect a malignant transformation rate of 1x10 minus 4, equivalent to the response to 1 Gy of 100 kVp X-rays or to about 2 Mug/ml of benzo(a)pyrene. Cells will be irradiated at 1.7 MHz in suspension in a transmission chamber at 37 degrees C using uniform (unfocused) beam profiles, with irradiation times ranging from 1 to 10 minutes. Emphasis will be placed on providing replicable, well-characterized ultrasound delivery and bioassay.

我们建议使用C3 H/10 T1/2来评估超声的致癌风险 恶性转化体外测定。 这种分析更直接 和致癌风险的定量测量，而不是突变或 染色体改变 超声波束被配置为模拟 诊断和治疗条件将用于照射细胞 单独，与致癌治疗（2戈伊的100-kVp X射线）联合， 或随后在0.1 μ g/ml的 12-0-十四酰基-佛波醇-13-乙酸酯（TPA），以研究 可能的致癌相互作用的共应激和肿瘤促进剂与 超声. 实验将被设计成检测一种恶性的 转化率为1 × 10 - 4，相当于对1戈伊 100 kVp X射线或至约2 μ g/ml苯并（a）芘。 细胞将被 在37度的传输室中以1.7 MHz的悬浮液照射 C使用均匀（未聚焦）光束轮廓，辐照时间范围 从1到10分钟。 重点将放在提供可复制、 良好表征的超声递送和生物测定。